ENZALUTAMIDE—A BOON TO CURE HIGHRISK NON-METASTATIC CASTRATIONRESISTANT PROSTATE CANCER

1. ENZALUTAMIDE—A BOON TO CURE HIGH- RISK NON-METASTATIC CASTRATION- RESISTANT PROSTATE CANCER Prostate cancer is the second most commonly occurring cancer in American men. Naturally, it originates in the prostate gland and spreads to the lymph nodes and other parts of the body gradually. In most of the early stages of prostate cancers, testosterone is required for the disease to spread. However, that is not the case in castrate-resistant prostate cancer. Even if the testosterone level is reduced to the lowest levels in the body, cancer keeps on growing. Mention may also be made that approximately 10-20% of the total number of diagnosed cases turn out to castrate-resistant. Through several clinical trials, the efficiency of several life-saving (or prolonging) metastatic castration-resistant prostate cancer therapies has been established. At the same time, it can also be said that the real-world application, data on survival effect and safety are still limited. According to recent findings, it has been proved that Enzalutamide has been successfully proven to be helpful for men with mCRPC rather than watchful observation with the conventional androgen deprivation therapy.

2. How is enzalutamide helpful for men with high- risk non-metastatic castration-resistant prostate cancer? A retrospective and non-interventional cohort analysis of electronic health record data of patients with mCRPC was conducted with the primary objective of describing the real-world treatment types, patterns, approximate duration and sequencing. The secondary objective of the study was to describe patient characteristics and clinical outcomes. A total of 2559 patients participated in the study out of which 77% was treated with 1 line of life-prolonging therapy. Among them, 49% got second-line therapy and 43%, third line. Abiraterone and Enzalutamide were present in 65% of first-line and 54% of second-line therapies with Docetaxel as the most common third-line therapy. Results With back to back the use of Abiraterone 250 mg and Enzalutamide 40 mg, the median overall survival was discovered to be much longer in patients who underwent the life-prolonging therapies (23.7 months) while the ones who did not have a median overall survival of 10.1 months. Therefore, the outcome category of mortality has an added advantage which proved that the patients who were treated with Enzalutamide survived longer than patients who were at the comparator wing of the study. Though the medication proved to be efficient in the treatment for renal and urinary disorders, the line between the symptoms of the disease and side effects of the drug has not yet been drawn clearly. Just like the added advantage, there are also disadvantages of this drug compared to the watchful observation along with androgen deprivation therapy. The extent of the side effects was considered to be minor to significant. However, researchers did not consider these to be severe because the overall assessment suggested longer survival.

3. Conclusion Enzalutamide has shown a groundbreaking impact on the treatment for metastatic castrate-resistant prostate cancer. The recommended dose is 160mg, i.e., 4 Enzalutamide 40mg tablets each day. It may, however, vary depending on several factors like the severity of the disease, the medical condition of the patient and so on. In some cases, it is also prescribed to shrink the tumor for surgery. Source:- http://ikrispharma.over-blog.com/enzalutamide-a- boon-to-cure-high-risk-non-metastatic-castration-resistant- prostate-cancer.html